INS and type 2 diabetes mellitus: There is some evidence for this; in a small clinical trial, Oral, Saltiel, and colleagues showed that an inhibitor of the proinflammatory kinases TBK1 and IKKε (amlexanox) improved insulin sensitivity in a subset of patients with T2D.